Loading
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Previous close
$0.9586
+$0.0427 · +4.66%
After-hours
$0.9805
+$0.0219 · +2.28%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Day range
Current $0.9586
52-week range
Current $0.9586
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
47
Mixed
Risk
70
High Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Day range
Current $0.9586
52-week range
Current $0.9586
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 25.66M USD | 48.22M USD | 29.46M USD | 47.31M USD | 44.94M USD |
| Selling, general, and administrative | 9.6M USD | 11.89M USD | 13.34M USD | 15.37M USD | 11.28M USD |
| Operating expenses | 35.27M USD | 60.12M USD | 42.79M USD | 62.68M USD | 56.22M USD |
| Interest income | 3.32M USD | 6.19M USD | 7.32M USD | 2.35M USD | 185.36K USD |
| Interest expense | 1.91M USD | 1.93M USD | 2.07M USD | 1.69M USD | 1.74M USD |
| Depreciation and amortization | 251.99K USD | 249.62K USD | 262.78K USD | 258.71K USD | 264.18K USD |
| Operating income | −35.27M USD | −60.12M USD | −42.79M USD | −62.68M USD | −56.22M USD |
| Net income | −33.85M USD | −55.85M USD | −37.54M USD | −62.02M USD | −57.78M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.67
908.76% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.64M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Extended Market ETFVXF849.03K0.00%95.4B USD0.05%$233.49-1.56%
Vanguard Health Care ETFVHT247.87K0.00%22B USD0.09%$315.31+0.78%
iShares Micro-Cap ETFIWC171.73K0.01%1.33B USD0.60%$183.36-1.09%
Invesco RAFI US 1500 Small-Mid ETFPRFZ94.33K0.00%2.68B USD0.36%$52.73-1.20%
Invesco NASDAQ Future Gen 200 ETFQQQS74.18K0.32%22.96M USD0.20%$42.026-1.20%
Dimensional - US Small Cap ETFDFAS36.49K0.00%34.14B USD0.31%$77.92-1.38%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZInvesco NASDAQ Future Gen 200 ETFQQQSDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
